To the Editor.—
In assessing the "double-blindness" of the β-Blocker Heart Attack Trial, Byington and colleagues1 have contributed an important set of observations. Their importance is magnified by the perceptive and well-written editorial of Dr Morgan.2 The next question that the authors may wish to deal with is: What were the results in those patients receiving placebo who believed they were on a drug regimen in comparison with the others receiving placebo and with those receiving drug? (Other potential subgroup comparisons are obvious.) The statistics on their outcomes must be readily available to the authors and, if significant differences can be exposed, would further affect the overall interpretation of the trial results.
Spodick DH. Double-blind as a BHAT. JAMA. 1985;254(6):755. doi:10.1001/jama.1985.03360060053019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: